11/21/2017  8:06:18 AM Chg. +0.640 Volume Bid9:14:19 AM Ask9:14:19 AM Market Capitalization Dividend Y. P/E Ratio
26.645EUR +2.46% 0
Turnover: 0.000
26.480Bid Size: 400 26.505Ask Size: 400 12.3 bill.EUR - -

Business description

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Management board & Supervisory board

Peer M. Schatz
Management board
Roland Sackers, Douglas Liu, Dr. Laura Furmanski, Dr. Thomas Schweins, Manuel O. Mendez, Thierry Bernard
Supervisory board
Prof. Dr. Manfred Karobath, Dr. Håkan Björklund, Dr. Metin Colpan, Elizabeth E. Tallett, Lawrence A. Rosen, Prof. Dr. Elaine Mardis, Prof. Dr. Ross L. Levine, Stéphane Bancel

Company data

Address: Spoorstraat 50,NL-5911 KJ Venlo
Phone: +31-77-320-8400
Fax: +31-77-320-8409
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 1,749.50%
IPO date: 9/25/1997

Investor relations

Name: John Gilardi
IR phone: +49-2103-29-11711
IR-Fax: +49 (0) 210 3292 1710
IR e-mail: john.gilardi@qiagen.com

Main Shareholders

Franklin Resources, Inc
BlackRock, Inc.
PRIMECAP Management Co.
Platinum Investment Management Ltd.